Study of Oral LOXO-338 in Patients With Advanced Blood Cancers
Completed · Phase 1 · NCT05024045
Conditions: Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-cell Marginal Zone, Lymphoma, Non-Hodgkin, Multiple Myeloma, B-cell Lymphoma, Waldenstrom Macroglobulinemia, Lymphoma, Mantle-Cell
At a glance
- Research payments reported, 2025
- $24,521
- U.S. investigators named
- 2
- Sites paid
- 2
- Planned or actual enrollment
- 27
About the trial
- Sponsor
- Eli Lilly and Company
- Tested
- LOXO-338 (drug), Pirtobrutinib (drug)
- Dates
- Started 2021-09-30; completion 2026-03-02
- Results posted
- Not yet
The purpose of this study is to find out whether the study drug, LOXO-338, is safe and effective in patients with advanced blood cancer. Patients must have already received standard therapy. The study may last up to approximately 3 years.
From ClinicalTrials.gov, last updated 2026-10-06. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Eli Lilly and Company reported $24,521 in research payments for this study in 2025 (2 payments).
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- City of Hope National Medical Ctr $20,521
- St. Francis Hospital & Health Center $4,000
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.